Opt-Out Provisions Up Parent Support for HPV Requirement

This article originally appeared here.
Share this content:
Opt-Out Provisions Up Parent Support for HPV Requirement
Opt-Out Provisions Up Parent Support for HPV Requirement

MONDAY, Aug. 22, 2016 (HealthDay News) -- Opt-out provisions increase parental support for human papillomavirus (HPV) vaccine school-entry requirements, according to a study published online Aug. 19 in Cancer, Epidemiology, Biomarkers & Prevention.

William A. Calo, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues surveyed a national sample of 1,501 parents of 11- to 17-year-olds to assess correlates of support for school-entry requirements for HPV vaccination.

The researchers found that 21 percent of parents agreed and 54 percent disagreed that laws requiring HPV vaccination for school attendance are a good idea. Agreement increased to 57 percent and disagreement dropped to 21 percent if school-entry requirements included opt-out provisions. Parents more often agreed with requirements without opt-out provisions if they were Hispanic, believed HPV vaccine was as important as other adolescent vaccines, or believed in the effectiveness of HPV vaccination for preventing cervical cancer (odds ratios, 1.53, 2.76, and 2.55, respectively). Parents who resided in Midwest states or those who believed that HPV vaccine was being promoted to make money for drug companies less often agreed (both P < 0.05).

"Our findings suggest that race/ethnicity, attitudes about HPV vaccine, and region of residence may influence support for requirements without opt-out provisions," the authors write.

One author disclosed financial ties to Merck and Pfizer; the study was funded by Merck Sharp & Dohme.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »